BETA vs DRAGARWQ: Stock Comparison
DR. AGARWAL'S EYE HOSP L is the larger company by market capitalisation. DR. AGARWAL'S EYE HOSP L shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BETA leads 2; DRAGARWQ leads 9 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BETA | DRAGARWQ |
|---|---|---|
| Live Price | ₹2,075 | ₹5,275.5 |
| Day Change | 0.49% | 0.11% |
| Volume | 4,969 | 585 |
| 52-Week High | ₹2,807.9 | ₹6,059.7 |
| 52-Week Low | ₹990.1 | ₹4,600 |
| Distance from 52W High | -26.1% | -12.94% |
Valuation
| Metric | BETA | DRAGARWQ |
|---|---|---|
| Market Cap | ₹2,303 Cr | ₹2,548 Cr |
| P/E Ratio | 50.32x | 33.43x |
| P/B Ratio | 8.53x | 7.36x |
| EPS | ₹5.35 | ₹48.38 |
| Book Value | ₹220.79 | ₹716.56 |
| Dividend Yield | 0% | 0.2% |
Growth
| Metric | BETA | DRAGARWQ |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | -55.53% | -69.64% |
| Qtr Profit Growth | -64.01% | -66.65% |
Profitability & Leverage
| Metric | BETA | DRAGARWQ |
|---|---|---|
| ROE | 9.58% | 20.24% |
| ROCE | 14.63% | 18.74% |
| Net Margin | 10.78% | 14.89% |
| Operating Margin | 13.32% | 22.4% |
| Debt to Equity | 0.87x | 0.24x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BETA | DRAGARWQ |
|---|---|---|
| Promoter Holding | 59.1%▼ 5.53 pp | 72.67% |
| FII Holding | 1.02%▼ 0.14 pp | 2.24%▲ 0.04 pp |
| DII Holding | 6.23%▲ 4.08 pp | 2.05%▼ 0.07 pp |
| Public Holding | 33.65%▲ 1.59 pp | 23.04%▲ 0.04 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BETA DRUGS and DR. AGARWAL'S EYE HOSP L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.